NEO2734

Also Known As:

1,3-Dimethyl-5-(2-(tetrahydro-2H-pyran-4-yl)-1-(2-(trifluoromethoxy)ethyl)-1H-benzimidazol-6-yl)-2(1H)-pyridinone; 2(1H)-Pyridinone, 1,3-dimethyl-5-(2-(tetrahydro-2H-pyran-4-yl)-1-(2-(trifluoromethoxy)ethyl)-1H-benzimidazol-6-yl)-

Networked: 8 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - NEO2734: 8
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - NEO2734: 8

Experts

1.	Giles, Francis: 4 articles (08/2021 - 01/2020)
2.	Huang, Haojie: 2 articles (01/2021 - 11/2019)
3.	Ma, Jian: 2 articles (01/2021 - 11/2019)
4.	Pan, Yunqian: 2 articles (01/2021 - 11/2019)
5.	Yan, Yuqian: 2 articles (01/2021 - 11/2019)
6.	Brown, Bill: 2 articles (01/2020 - 01/2020)
7.	Wahlestedt, Claes: 2 articles (01/2020 - 11/2019)
8.	Ji, Donglei: 1 article (01/2022)
9.	Jia, Yanjie: 1 article (01/2022)
10.	Shang, Guanglei: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 11/07/2019 - "These data provide a strong rationale to clinically investigate the anti-cancer efficacy of NEO2734 in SPOP-mutated PCa patients." 01/01/2022 - "Finally, we show that NEO2734 monotherapy is able to suppress tumor growth in CRC xenografts by inducing apoptosis. " 01/01/2021 - "The dual inhibitor NEO2734 showed strong anti-tumor activity and was consistently highly active against all MMCLs, being as potent as JQ1 and more so than other single inhibitors. " 01/01/2020 - "Here, we characterize the antitumor activity of the pan BET/CBP/EP300 inhibitor NEO2734 and provide insights into its mechanism of action through bromodomain-binding assays, in vitro and in vivo treatments of cancer cell lines, immunoblotting, and transcriptome analyses. " 01/01/2020 - "In three disseminated NMC xenograft models, NEO2734 provided greater growth inhibition, with tumor regression and significant survival benefit seen in two of three models, compared with a lead clinical BET inhibitor or "standard" chemotherapy. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/01/2021 - "The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells."
3.	Prostatic Neoplasms (Prostate Cancer) 11/07/2019 - "The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer." 01/01/2020 - "In a panel of 60 models derived from different tumor types, NEO2734 exhibited antiproliferative activity in multiple cell lines, with the most potent activity observed in hematologic and prostate cancers. " 01/01/2020 - "In conclusion, NEO2734 is a novel antitumor compound that shows preferential activity in lymphomas, leukemias, and prostate cancers."
4.	Neoplasm Metastasis (Metastasis) 01/01/2022 - "Our biochemical and structural analyses further showed that NEO2734, a dual-inhibitor targeting BRD4 and p300 bromodomains exhibits greater efficacy than single inhibitors for BRD4 or CBP/p300 in suppressing CDCP1 transcriptional expression and its downstream signaling pathways in CRPC cell proliferation and metastasis. "
5.	Multiple Myeloma 01/01/2021 - "Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	palbociclib
3.	OTX015

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)